Cart
sales@molnova.com
Norcantharidin b
CAS No. 29745-04-8
Norcantharidin b( Endothall anhydride )
Catalog No. M20338 CAS No. 29745-04-8
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 45 | In Stock |
|
| 25MG | 64 | In Stock |
|
| 50MG | 96 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNorcantharidin b
-
NoteResearch use only, not for human use.
-
Brief DescriptionNorcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
-
DescriptionNorcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
-
In Vitro——
-
In Vivo——
-
SynonymsEndothall anhydride
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorEGFRc-Met
-
Research AreaCancer
-
IndicationCancer
Chemical Information
-
CAS Number29745-04-8
-
Formula Weight168.15
-
Molecular FormulaC8H8O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:33 mg/mL (196.25 mM)
-
SMILES[H][C@@]12[C@H]3CC[C@H](O3)[C@]1([H])C(=O)OC2=O
-
Chemical Name47-Epoxyisobenzofuran-13-dione hexahydro- (3a-alpha4-beta7-beta7a-alpha)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Qiu P Wang S Liu M et al. Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells[J]. BMC Cancer 2017 17(1):55.
molnova catalog
related products
-
Emibetuzumab
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
-
Rilotumumab
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling.
-
Capmatinib
Capmatinib (INCB-28060, INC-280) is a highly potent, selective, ATP competitive inhibitor of c-MET kinase with IC50 of 0.13 nM.
